Lenvatinib

Lenvatinib is an antineoplastic agent belonging to the class of tyrosine kinase inhibitors. It works by blocking the activity of specific proteins (VEGF, FGFR, PDGFR, KIT, and RET receptors) involved in cancer cell growth and the formation of new blood vessels (angiogenesis) that supply the tumor. The drug is indicated for the treatment of differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.